Ann: OFFICE: FPH: Confirmation of Appointment of MD/CEO & Appointment of VP

• Release Date: 31/03/16 15:26
• Summary: OFFICE: FPH: Confirmation of Appointment of MD/CEO & Appointment of VP
• Price Sensitive: No
• Download Document  3.69KB

					FPH
31/03/2016 15:26
OFFICE
NOT PRICE SENSITIVE
REL: 1526 HRS Fisher & Paykel Healthcare Corporation Limited

OFFICE: FPH: Confirmation of Appointment of MD/CEO & Appointment of VP

CONFIRMATION OF APPOINTMENT OF MANAGING DIRECTOR/CEO AND APPOINTMENT OF VP -
PRODUCTS & TECHNOLOGY

Auckland, New Zealand, 31 March 2016 - Following the announcement in August
2015 that Michael Daniell would retire as Managing Director and Chief
Executive Officer of Fisher & Paykel Healthcare, the company today advises
that Lewis Gradon has now been appointed as Managing Director and Chief
Executive Officer, effective 1 April, 2016.

Mr Gradon has most recently served as the company's Senior Vice President -
Products & Technology, a role he has held since 2001. Prior to that time he
was General Manager - Research & Development. "Lewis' strong technology
background, combined with his thorough understanding of the business and its
markets means he is well placed to take the company forward as we continue to
deliver on our consistent growth strategy," says Chairman of the Board, Tony
Carter.

The company also advises that Dr Andrew Somervell has been appointed Vice
President - Products & Technology to fill the role previously held by Lewis
Gradon.

Since joining Fisher & Paykel Healthcare in 2006, Dr Somervell has held
various product development and operations management roles, and most
recently was General Manager   Product Groups. He has overseen the
development of the OSA product range and managed research and development,
marketing, clinical, manufacturing, and aspects of the supply chain. Before
joining Fisher & Paykel Healthcare, Andrew was a Research Fellow at the
University of Auckland, New Zealand, and holds a doctorate in physics from
the same university.

"Andrew has been in senior roles with the company for 10 years, and in that
time has contributed significantly to our product development, particularly
in his most recent role as General Manager - Product Groups and prior to
that, General Manager of the OSA product range," says Mr Gradon. "I am
pleased that Andrew is moving into this new role and am sure the team will
flourish under his leadership."

Mr Carter also acknowledged the significant contribution that Michael Daniell
has made to the company. "Over the past 37 years Mike has filled a number of
different roles within the company and has led the healthcare business since
1990," says Mr Carter. "He has lead a team that has taken the company from a
small medical division of an iconic New Zealand appliance manufacturer to the
global leader in respiratory humidification, with a market capitalisation of
more than 5 billion New Zealand dollars, more than 3,500 employees and over
730 million dollars in assets."

Mr Daniell will remain a member of the company's Board of Directors. In
accordance with NZX Listing Rule 3.3.3(a), the Board has determined that
Lewis Gradon is not an independent director by virtue of his executive
position as Managing Director and Michael Daniell is not an independent
director due to his transition from the role of Chief Executive Officer and
Managing Director.

The factors that the Board considers in assessing the independence of
directors are set out in the Board Charter, which can be viewed on the
company's website at www.fphcare.com/corporategovernance.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer
of products and systems for use in respiratory care, acute care, surgery and
the treatment of obstructive sleep apnea. The company's products are sold in
more than 120 countries worldwide. For more information about the company,
visit our website www.fphcare.com.
End CA:00280116 For:FPH    Type:OFFICE     Time:2016-03-31 15:26:55